Impact of concomitant carcinoma in situ distribution on non‐muscle‐invasive bladder cancer progression risk

This is the authors' abstract. We don't add key points for this paper.

Papillary NMIBC progression risk varies with concomitant CIS distribution. Only multifocal concomitant CIS is a risk factor for progression in patients with T1 NMIBC. If validated in further studies, risk calculators should consider including this CIS distinction. Submitting separate specimens at the time of transurethral resection, as recommended by guidelines, should be encouraged.